Adam D. Cohen, MD, Director of the Myeloma Immunotherapy Program at the Abramson Cancer Center, offers a primer on recent advances in targeted immunotherapy for multiple myeloma (MM). Dr Cohen's presentation includes a discussion of the phase 1 study of the anti-BCMA immunoconjugate GSK2857916 in subjects with relapsed/refractory MM, as well as a comprehensive review of the mAbs, vaccines, immune checkpoint inhibitors, IMiDs, BiTEs (bispecific T cell engagers) and anti-BCMA CAR T cell therapies, their clinical studies, prospective indications and mechanisms of action.
Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Dr. Cohen’s Profile
Connect on Doximity